logo-loader
viewActinogen Medical Ltd

Actinogen Medical in an ASX trading halt

Actinogen Medical (ASX:ACW) has been granted a trading halt by the ASX, with its shares placed in pre-open.

ASX-Exchange-Centre-Bridge-St-757-highres.jpg
Actinogen has been granted a trading halt.

Actinogen requested the halt pending details regarding Actinogen Medical’s application to the FDA to initiate its XanADu Phase II clinical trial in the US of Xanamem in the treatment of Alzheimer’s disease.

The halt will remain in place until the opening of trade on Wednesday 4th January 2017, or earlier if an announcement is made to the market.

Quick facts: Actinogen Medical Ltd

Price: 0.045 AUD

ASX:ACW
Market: ASX
Market Cap: $50.37 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Piedmont Lithium secures landmark Section 404 Permit to...

Piedmont Lithium Ltd (ASX:PLL) CEO Keith Phillips tells Proactive the lithium explorer has received the Section 404 Permit under the Clean Water Act from the US Army Corps of Engineers for its lithium project in North Carolina. Phillips says this landmark achievement follows a fair, albeit...

2 days, 7 hours ago

2 min read